In an updated analysis of a phase 2 RCT of 108 Chinese patients with advanced GIST, ripretinib vs sunitinib gave a non-significant overall survival difference (median 43.3 vs 29.9 months; HR 0.681, 95% CI 0.411-1.126); third-line PFS was comparable.
RCTn = 108
Zhang et al. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial